DE69204639T2 - Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels. - Google Patents
Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels.Info
- Publication number
- DE69204639T2 DE69204639T2 DE69204639T DE69204639T DE69204639T2 DE 69204639 T2 DE69204639 T2 DE 69204639T2 DE 69204639 T DE69204639 T DE 69204639T DE 69204639 T DE69204639 T DE 69204639T DE 69204639 T2 DE69204639 T2 DE 69204639T2
- Authority
- DE
- Germany
- Prior art keywords
- modafinil
- induced
- treatment
- dose
- manufacture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960001165 modafinil Drugs 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 4
- 230000002253 anti-ischaemic effect Effects 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 210000001723 extracellular space Anatomy 0.000 claims description 5
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 abstract description 3
- 102100033902 Endothelin-1 Human genes 0.000 description 11
- 101800004490 Endothelin-1 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 10
- 229960004046 apomorphine Drugs 0.000 description 10
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000003447 ipsilateral effect Effects 0.000 description 4
- 210000000337 motor cortex Anatomy 0.000 description 4
- 210000001577 neostriatum Anatomy 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003955 neuronal function Effects 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 238000001265 Jonckheere trend test Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 238000010826 Nissl staining Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000003970 cerebral vascular damage Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 230000009688 glial response Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/065—Diphenyl-substituted acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9115534A FR2684875B1 (fr) | 1991-12-13 | 1991-12-13 | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69204639D1 DE69204639D1 (de) | 1995-10-12 |
| DE69204639T2 true DE69204639T2 (de) | 1996-04-04 |
Family
ID=9420051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69204639T Expired - Lifetime DE69204639T2 (de) | 1991-12-13 | 1992-12-11 | Verwendung von Modafinil zur Herstellung eines antiischämischen Arzneimittels. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5391576A (enExample) |
| EP (1) | EP0547952B1 (enExample) |
| JP (1) | JPH0825873B2 (enExample) |
| KR (1) | KR100252390B1 (enExample) |
| AT (1) | ATE127342T1 (enExample) |
| AU (1) | AU656642B2 (enExample) |
| DE (1) | DE69204639T2 (enExample) |
| DK (1) | DK0547952T3 (enExample) |
| FR (1) | FR2684875B1 (enExample) |
| HU (2) | HU9203921D0 (enExample) |
| TW (1) | TW244335B (enExample) |
| UA (1) | UA27231C2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| FR2706767B1 (enExample) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2708201B1 (fr) * | 1993-06-30 | 1995-10-20 | Lafon Labor | Utilisation de dérivés d'acétamide pour la fabrication de médicaments. |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| DE19943983A1 (de) * | 1999-09-14 | 2001-03-15 | Joseph Clasen | Verwendung von Modafinil zur Herstellung eines plastizitätsfördernden Arzneimittels |
| US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| IL155322A0 (en) * | 2000-10-11 | 2003-11-23 | Cephalon Inc | Compositions comprising modafinil compounds |
| US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7704975B2 (en) * | 2000-12-19 | 2010-04-27 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| WO2004075841A2 (en) * | 2003-02-24 | 2004-09-10 | Mallinckrodt Inc. | Process for preparing benzhydrylthioacetamide |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| US20060024370A1 (en) | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
| EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
| WO2013062316A2 (ko) * | 2011-10-25 | 2013-05-02 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 혈관질환 또는 ＫＣａ3.1 채널 매개 질환 치료용 조성물 |
| KR101345860B1 (ko) | 2011-10-25 | 2013-12-30 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물 |
| KR101414831B1 (ko) * | 2011-10-25 | 2014-07-04 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 ＫＣａ3.1 채널 매개 질환 치료용 조성물 |
| EP3854409A1 (en) | 2013-08-30 | 2021-07-28 | Green Cross Wellbeing Corporation | Composition for preventing and treating cancer-related fatigue, containing processed ginseng powder or processed ginseng extract having increased ginsenoside constituent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
-
1991
- 1991-12-13 FR FR9115534A patent/FR2684875B1/fr not_active Expired - Lifetime
-
1992
- 1992-12-10 AU AU30080/92A patent/AU656642B2/en not_active Expired
- 1992-12-11 DE DE69204639T patent/DE69204639T2/de not_active Expired - Lifetime
- 1992-12-11 EP EP92403381A patent/EP0547952B1/fr not_active Expired - Lifetime
- 1992-12-11 HU HU9203921A patent/HU9203921D0/hu unknown
- 1992-12-11 HU HU9203921A patent/HU216193B/hu unknown
- 1992-12-11 AT AT92403381T patent/ATE127342T1/de active
- 1992-12-11 DK DK92403381.4T patent/DK0547952T3/da active
- 1992-12-12 KR KR1019920024095A patent/KR100252390B1/ko not_active Expired - Lifetime
- 1992-12-14 JP JP4332897A patent/JPH0825873B2/ja not_active Expired - Lifetime
- 1992-12-14 US US07/988,271 patent/US5391576A/en not_active Expired - Lifetime
-
1993
- 1993-01-27 TW TW082100506A patent/TW244335B/zh not_active IP Right Cessation
- 1993-06-18 UA UA93002196A patent/UA27231C2/uk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0547952A1 (fr) | 1993-06-23 |
| DK0547952T3 (da) | 1996-01-22 |
| HU9203921D0 (en) | 1993-03-29 |
| FR2684875A1 (fr) | 1993-06-18 |
| HUT67784A (en) | 1995-04-28 |
| JPH0665070A (ja) | 1994-03-08 |
| EP0547952B1 (fr) | 1995-09-06 |
| US5391576A (en) | 1995-02-21 |
| DE69204639D1 (de) | 1995-10-12 |
| ATE127342T1 (de) | 1995-09-15 |
| AU3008092A (en) | 1993-06-17 |
| FR2684875B1 (fr) | 1995-05-24 |
| TW244335B (enExample) | 1995-04-01 |
| JPH0825873B2 (ja) | 1996-03-13 |
| AU656642B2 (en) | 1995-02-09 |
| KR100252390B1 (ko) | 2000-05-01 |
| HU216193B (hu) | 1999-05-28 |
| KR930012022A (ko) | 1993-07-20 |
| UA27231C2 (uk) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69112717T2 (de) | Neue Verwendung von Modafinil. | |
| KR100252390B1 (ko) | 뇌조직 보호용 모다피닐(Modafinil) | |
| DE60009346T2 (de) | Buprenorphin enthaltende analgetische zusammensetzungen | |
| DE3247062C2 (enExample) | ||
| DE69022953T2 (de) | Zusammensetzungen zur Behandlung von Fettablagerungen. | |
| DE19542281A1 (de) | Verwendung von Epinastin für die Behandlung von Schmerzen | |
| RU2095060C1 (ru) | Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний | |
| DE4220851A1 (de) | Verwendung von schwefel enthaltenden carbonsaeuren zur bekaempfung von pathophysiologisch bedingten erregungsstoerungen und von hierdurch bedingten erkrankungen sowie von allergischen erkrankungen sowie die herstellung entsprechender arzneimittel | |
| DE69524662T2 (de) | Topisches Arzneimittel mit vernarbungsfördernder Wirkung | |
| DE69024053T2 (de) | Behandlung zur ermässigung von ödem und muskelschäden. | |
| DE69413090T2 (de) | Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel | |
| EP0345247A2 (de) | Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung | |
| DE602004003176T2 (de) | Kräutermineralzusammensetzung für refraktäre Leukämien und Lymphome | |
| DE60203106T2 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
| DE2611976A1 (de) | Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden | |
| AT402691B (de) | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome | |
| DE4206233C1 (en) | Use of Bellis Perennis extract - for treatment and prevention of hypoxia caused by e.g. cerebral ischaemia | |
| EP0207882B1 (de) | Verwendung von Tergurid zur Herstellung eines Arzneimittels zur Behandlung geriatrischer Beschwerden | |
| DE69807586T2 (de) | Verwendung eines Alkylendioxybenzolderivats zur Behandlung von zirkadianen Schlafstörungen | |
| DE60313785T2 (de) | Kombinierte verwendung von melatonin und methylphenidat zur behandlung von aufmerksamkeits-/hyperaktivitätsstörungen. | |
| DE3519736C2 (de) | Mittel zur Behandlung von Rheuma und Polyarthritis | |
| EP0523591A2 (de) | Verwendung eines Kava-Extraktes und seiner Inhaltsstoffe | |
| EP4153206A1 (de) | Pflanzliche verbindungen zur behandlung der alzheimer krankheit | |
| DE19853425A1 (de) | Khellin-Zubereitung und deren Verwendung zur topischen Therapie der Psoriasis, ihrer Subtypen, Sonderformen, sowie zur topischen Therapie von Ekzemen | |
| DE3043909A1 (de) | Arzneimittel, enthaltend eine kombination von acetylsalicylsaeure und heptaminol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right |
Ref document number: 547952 Country of ref document: EP |